Researchers have identified a new drug, URB597, which enhances endocannabinoid levels in the brain, potentially offering a safer alternative to cannabis for treating depression and pain. Published in the Proceedings of the National Academy of Sciences, the study indicates that URB597 works by inhibiting the breakdown of endocannabinoids, leading to significant antidepressant effects. This discovery could pave the way for improved treatments for clinical depression, a condition affecting about 20% of Canadians. Additional discussions highlight previous findings on cannabinoids, including synthetic compounds like HU210, which have shown promise in promoting neurogenesis and reducing anxiety and depression in rats. However, contrasting studies have reported no neurogenesis linked to THC, the primary psychoactive component of cannabis. Overall, the emerging research suggests that cannabinoids may have beneficial effects on brain health, although results can vary significantly between different compounds.